~//bj.watch/overview
live

concept dossier

Immortality by 2039

“Immortality by 2039” is bryan johnson's stated aspirational target for blueprint and dont die. In a 2026-01-30 Blueprint article, he says: “by 2039, my goal is immortality,” while explicitly acknowledging he may fail. He operationalizes success as one year of chronological time passing while biological age stays the same.

longevitypredictionai-safetyideologybiohackingopen-question

// Habits · Longterm · Don’ts

Immortality by 2039: habits, longterm, and don’ts

Three buckets keep practical routines, long-range interpretation, and source-aware caution visible on every protocol surface.

repeatable behaviors

Habits

  • Prioritize measured healthspan basics: exercise, sleep regularity, nutrition, risk-factor monitoring, and clinician-guided prevention.concepts/biomarker-driven-longevity-protocols.md
  • Read biological-age and speed-of-aging numbers as tracked claims with source trails and critique links nearby.raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md
durable strategy

Longterm

  • Treat Johnson’s October 2026 bone-pressure lifespan post as an attributed research claim that self-corrected the same day — the “+80 days (+9.4%)” figure now traces to a real paper, but the paper is mice, and its loading is a machine. Johnson’s October 24 follow-up (“Here is the correct paper for the stats in the original post”) identifies Bai et al., “Dynamic force sensing by bone delays aging and extends lifespan,” Cell Metabolism, published online October 23, 2026 (10.1016/j.cmet.2026.09.020): dynamic tibial axial loading (2 N at 2 Hz, 300 cycles, twice weekly) in mice at 20–24 months extended median lifespan 9.4%/79.5 days, reversed bone-marrow immunosenescence, reduced liver steatosis, and improved cognition and endurance, covering the post’s brain/liver/immune triad; the correction’s PGE2 mechanism sentence traces to the same group’s Cx43-hemichannel work (Zhao et al., eLife 2022, 10.7554/eLife.74365). Boundaries: one mouse study published one day before the post; the loader is an external calibrated device compressing an anesthetized tibia, not jumping; the “human equivalent of 7–9 yrs” is arithmetic on the mouse percentage; no human loading evidence exists. Not evidence that jumping or dunk training extends life, a reader exercise prescription, or medical advice.https://x.com/bryan_johnson/status/2113992318206497133
  • Read Johnson’s October 2026 IL-11 lifespan relay as a verified paper carried with a drifted figure. The work is real and landmark: Widjaja et al., “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan,” Nature, July 17, 2024 (10.1038/s41586-024-07701-9) — anti-IL-11 antibody from 75 weeks until death extended median mouse lifespan 22.5% in males and 25% in females, with fewer tumours at autopsy, and Boehringer Ingelheim’s Phase IIa IPF trial of BI 765423 (announced January 13, 2026) makes the “Phase II human clinical trials for lung fibrosis” leg real. But the relay’s “35% in female mice” misquotes the paper (25%) and Johnson’s own July 17, 2024 post, which quoted both figures correctly — the same transcription-drift class as the bone-pressure figure two days earlier. Boundaries: mouse antibody dosing and knockout genetics; no human longevity data; the IPF trial tests lung function, not aging endpoints. Not evidence for anti-IL-11 in humans, a drug expectancy, or medical advice.https://x.com/bryan_johnson/status/2114834793296978182
  • Treat Johnson’s October 2026 psilocybin-Parkinson’s relay as a real three-day-old letter with every design limitation dropped. The study verifies: Bradley, Kelley, et al., JAMA Psychiatry research letter, published October 21, 2026 (10.1001/jamapsychiatry.2026.2733) — banked blood from 9 of 12 participants in the UCSF open-label pilot (NCT04932434), five inflammatory markers still significantly below baseline a month after the final 25-mg dose, GDF15 improving right after dosing then losing the gain at follow-up. The relay’s “In 9 Parkinson’s patients” hides that this is an uncontrolled, unblinded subsample of a 12-person safety pilot whose authors say the signal needs controlled confirmation; inflammatory markers move with sleep, stress, infection, and lifting depression; co-author disclosures include psychedelic-industry ties. Not evidence psilocybin treats Parkinson’s, a psychedelic-use endorsement, or medical advice.https://x.com/bryan_johnson/status/2114361011474215200
  • Separate durable healthspan practices from frontier enhancement, drug-stack, gene-therapy, and immortality narratives.concepts/biomarker-driven-longevity-protocols.md
  • Treat Johnson’s October 2026 “Resting heart is the new thirst trap” post as an attributed ideology-and-marketing disclosure, not health guidance. The mortality predictor verifies: the CMAJ 2016 meta-analysis of 46 cohorts (10.1503/cmaj.150535; 1,246,203 adults, 78,349 deaths) found each 10 bpm higher resting heart rate at all-cause mortality RR 1.09 (95% CI 1.07–1.12) and RHR >80 bpm at RR 1.45, with publication bias and no guideline endorsement. The self-reported 207-post/366,220-like/78.3M-view campaign metrics, the RHR-41 “perfect night sleep” promise, and “I promise every part of your life will improve” are marketing claims, not evidence; a predictor of mortality is not proof that a routine lowers risk. Not a sleep protocol, a health directive, or medical advice.https://x.com/bryan_johnson/status/2111149094576202049
  • Treat Johnson’s October 2026 “I can’t find a way to use my genome” post as an attributed negative-result admission, not a verdict on genome sequencing. The prevalence context verifies: the deCODE study of 57,933 Icelanders (NEJM, 10.1056/NEJMoa2300792) found 4.0% carry an actionable ACMG SF v3.0 genotype (~96% carry none), Korea’s national pilot found 3.75% of 7,472 genomes, Qatar’s program found 3.5%, and WA HCA’s 2024 WGS review reported ACMG-actionable findings in 0–12.5% of tested persons with very-low certainty of management change. The $7,902 matched 30x long-read + 100x short-read resequencing is a program claim; one null result does not cover carrier screening, pharmacogenomics, or diagnostic contexts. Not a testing recommendation for or against sequencing, or medical advice.https://x.com/bryan_johnson/status/2110438813122359731
  • Treat Johnson’s October 2026 “The Blue Zones are an illusion” post as an attributed amplification of a contested debunking, not a settled demographic finding. The underlying records verify: Japan’s 2010 audit found 82% of listed centenarians deceased (~230,000 people), Italy’s 1997 pension audit found ~30,000 dead “living” recipients, Costa Rica’s 2008 review found 42% of alleged centenarians had misstated ages, and Newman’s Ig Nobel-winning work documents age-records problems across Blue Zone regions. But the critique (Saul Justin Newman, non-peer-reviewed preprint) is disputed by working demographers and gerontologists — Sardinia’s Blue Zone researchers defend their validated records, and independent evidence for activity, moderate intake, and social connection stands regardless of the hotspot claims. Not a settled finding that no population exhibits exceptional longevity, a dietary directive, or medical advice.https://x.com/bryan_johnson/status/2110155459781112084
  • Treat Johnson’s September 2026 semaglutide mouse-lifespan post as an attributed research summary, not a longevity signal for humans. The study is real (Feng et al., Nature, 10.1038/s41586-026-10940-7: 20-month-old female C57BL/6 mice, median lifespan 742→834 days, endurance/memory/glucose gains, calorie-restriction-matched control), but it is one strain, female-only, mouse-only, median lifespan—and Johnson’s Immortals Rx sells GLP-1 medications, making the amplification commercially adjacent. Not human evidence, medication guidance, or medical advice.https://x.com/bryan_johnson/status/2100746261964202305
  • Treat the September 2026 organ-aging schedule post as an attributed research summary. The figures match PathStAR (bioRxiv 2025.09.29.679316; Nature Aging: 25,306 postmortem GTEx biopsies, 970 donors aged 21–70, 40 tissues, 30.3M image patches, age-blind training) and describe population-level tissue-architecture schedules—early vascular aging in the 30s, late uterus/vagina aging in the 50s, biphasic ovary and digestive/male-reproductive tissues—not a personal organ-age test or clinical risk model.https://x.com/bryan_johnson/status/2097458211670589449
  • Treat the September 2026 Immortals Concierge pricing disclosure ($75,000 to $1,000,000 memberships) as a commercial milestone, not an efficacy signal. The service list (physician, coach, 200+ biomarker panel, whole-body MRI) is a concrete disclosure; the “world-exclusive” immune cryopreservation and iPSC age-reversal claims are not evidence of established clinical services, and the efficacy argument is Johnson’s own testimonial biomarkers.https://x.com/bryan_johnson/status/2098148080025846005
  • Treat the September 2026 Eight Sleep biological-age model as a commercial measurement claim with a real but unreviewed preprint behind it. The post’s figures track BCG-FM (Kjaer et al., arXiv:2606.07692: 2.04M hours / 136,575 participants; 3.26-year MAE; diabetes 0.852, heart failure 0.822, hypertension 0.810, sleep apnea 0.792 AUROC), but the product is a membership feature co-developed with Johnson’s Immortals, its internal disease labels are self-reported, and it is not a diagnostic device by the post’s own words. Not a validated longevity measurement, a purchasing signal, or medical advice.https://x.com/bryan_johnson/status/2095675388810936586
  • Classify daily Tadalafil/Cialis and similar drug claims as hypothesis-generating prescription-intervention claims unless independent clinical evidence supports the exact longevity use case.raw/articles/bryan-johnson/x-twitter-daily-2026-06-13.md
  • Classify Immortals Rx GLP-1, SGLT2, peptide, and NAD+ listings as commercial platform expansion; do not treat off-label longevity positioning as proven outcome evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
  • Classify the July 2026 six-option GLP-1 catalog as a more specific commercial listing, not validation of weight-loss or longevity efficacy, compounded-treatment safety, prescribing criteria, formulation status, or availability.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
  • Classify Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence, product-adjacent intervention claim. The post itself labels the study preclinical and human evidence observational, and its extension from sildenafil to tadalafil is not established treatment evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
  • Classify sauna/HSP27 claims as mechanistic biomarker self-experimentation unless replicated and tied to clinically meaningful outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
  • Classify the July 2026 sauna checklist as an attributed expansion from N=1 biomarker testing into public protocol guidance; its frequency, heat-dose, fertility, microplastics, recovery, hydration, and environmental claims require independent evidence and safety context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
  • Classify the Midjourney scanner essay as a measurement-modality argument; structural imaging may complement chemical and functional data, but the third-party device and routine-screening claims need validation.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
  • Classify Johnson’s June 2026 wearable reply as a relative-tracking claim: consistency can help trend detection, but it does not settle absolute accuracy or clinical validity.raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md
  • Classify the inherited-cancer DNA + RNA panel as early-risk surveillance framing: useful for understanding Johnson’s measurement stack, not evidence that broad genetic screening improves outcomes for every reader.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
  • Classify the July 2026 single-cell immune sequencing thread as an AIG diagnostic/readout extension, not as proof that Johnson has a validated antigen-specific therapy.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
  • Classify the July 2026 low-ferritin / Monoferric follow-up as self-reported diagnostic follow-through and a false-negative argument, not as generalized iron-infusion guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
  • Classify the July 2026 AIG cure roadmap as a staged, investigational personal experiment; the “Bryan in a dish” ex-vivo model and candidate precision therapies are not established clinical outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
  • Classify the July 2026 Kate Tolo endometriosis workup as a female-health measurement case study: complementary tests can expose false negatives, but Johnson’s case narrative is not a validated general protocol or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
  • Classify the July 2026 1,900-biomarker / 14.8M-data-point Kate Tolo announcement as measurement-scale ambition. It is a planned N=1 collection program, not completed or independently validated female-health evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Classify Johnson’s July 2026 disease-resolution/frontier-biotech pivot as strategic positioning. The disease and proposed research program are unspecified, so the announcement is not evidence of a cure or protocol change readers can act on.raw/articles/bryan-johnson/x-twitter-daily-2026-07-21.md
  • Classify Johnson’s July 2026 autologous iPSC “clone” post as speculative regenerative-biotech positioning. It supplies no cell-line characterization, cited trial, organ, delivery method, safety evidence, or outcome and is not evidence of a human clone or available treatment.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
  • Classify Immortals’ July 2026 disease-resolution infrastructure expansion as strategic frontier-biotech positioning. Naming iPSCs, organoids, deep cellular characterization, and personalized therapy development does not establish a clinically available platform or evidence of diagnosis, treatment, safety, cure, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
  • Classify the July 2026 operational Kate Tolo baseline as measurement-scale ambition and protocol operations. The 100-day N=1 plan is not completed or independently validated female-health evidence, and its sensitive-data methods and governance remain unpublished.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
  • Classify Johnson’s August 2026 brain-clearance post as an uncited, preclinical research lead. The source describes one intranasal gene therapy in mice but supplies no named paper, human evidence, translational safety data, Blueprint intervention, or clinical outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
  • Classify Johnson’s August 2026 mRNA–Keytruda post as third-party research commentary. He describes a tumor-fingerprint mRNA therapy paired with Keytruda in a first Phase 3 trial but names no trial, paper, sponsor, or data, so it is not a Blueprint intervention, an available treatment, or medical advice.https://x.com/bryan_johnson/status/2090212567235149828
  • Keep the Immortals rename and immortality search-trend narrative in the ideology/brand lane; it does not increase confidence in the 2039 forecast.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
  • Keep the June 2026 immortality manifesto and “Die Economy” frame in the ideology/forecast lane unless independent evidence supports the specific biological and AI claims.raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md
  • Keep critiques visible so biomarker improvements do not become unsupported longevity promises.raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md
guardrails

Don’ts

  • Do not render “immortality by 2039” as a realistic forecast or medical endpoint.concepts/immortality-by-2039.md
  • Do not collapse Johnson’s ideology, Blueprint marketing, and independent evidence into one confidence level.concepts/biomarker-driven-longevity-protocols.md

Immortality by 2039

“Immortality by 2039” is bryan johnson’s stated aspirational target for blueprint and dont die. In a 2026-01-30 Blueprint article, he says: “by 2039, my goal is immortality,” while explicitly acknowledging he may fail. He operationalizes success as one year of chronological time passing while biological age stays the same.

Argument structure

Johnson’s argument has four parts:

  1. Biology has examples of extreme longevity / agelessness: he invokes hydra, Turritopsis dohrnii, and lobster telomerase as motifs that nature has solved pieces of the problem.
  2. Aging is an engineering problem: immortality is framed as biological engineering, not a physics impossibility.
  3. AI accelerates discovery: AI moving from assistant to scientist plus richer biomarker measurement could create a closed-loop improvement system.
  4. Blueprint is the personal prototype: six years of measurement, interventions, and iteration allegedly produced elite-young adult levels in several systems, while revealing remaining deficits.

Implementation direction

The article says Johnson is having thousands of organ clones built in dishes to test drugs and molecules against his own biology. The goal is to accelerate learning while reducing direct bodily risk.

Philosophical / AI dimension

Johnson says the 2039 goal is not only about living forever; it is a way to focus collective attention on a positive goal and move society from YOLO to dont die. He frames this as part of surviving superintelligence: if AI changes everything, society needs a stabilizing aspiration around existence.

On X, he often repeats adjacent formulations: humans may be “the first generation to not die,” lifespans may become so long that people stop thinking about lifespans, and Blueprint is becoming infrastructure for people who want to “play the immortality by 2039 game.”

On June 19, 2026, Johnson reinforced the same frame by explicitly announcing that the company has changed its name to Immortals and by publishing a search-trend essay that portrays “Bryan Johnson” and “immortality” as rising together since 2022. The underlying search data source was not cited in the tweet, so the dashboard treats this as Johnson’s narrative about legitimacy and cultural momentum, not independent analytics. It strengthens the evidence that immortality is central to the brand, but it does not raise confidence in the 2039 forecast.

On June 24, 2026, Johnson published his most explicit structured immortality argument to date. He defined the target as life-expectancy gains outpacing the rate of aging, then argued from three buckets: biology already contains age-reset or escape motifs (embryos, Turritopsis, iPSCs, partial reprogramming), AI can solve biological complexity (AlphaFold2 as the exemplar), and early AI-assisted cancer anecdotes look encouraging. The cancer examples — Sid Sijbrandij’s AI-directed personalized therapy account and Paul Conyngham’s dog mRNA-vaccine story — are Johnson’s retelling in a tweet capture, not independently verified evidence here. The essay also adds a practical tier: “don’t die in the meantime,” find the weakest system that could kill you before future therapies arrive, and invest in AI / Immortality / Energy. This is important for understanding the thesis, but it does not raise confidence in the 2039 forecast.

On July 21, 2026, Johnson described a newborn version of himself living in a petri dish and framed autologous reprogrammed cells as a possible platform for therapy testing, organ growth, new treatments, and young-cell transplantation. He attributed the proposed process to Yamanaka factors resetting epigenetic age and producing pluripotent cells, and pointed generally to related clinical-trial work. The post extends the earlier organ-clone implementation story but supplies no cell-line characterization, named trial, organ, delivery method, safety evidence, or outcome. The dashboard therefore treats “clone” as Johnson’s metaphor for a dish-grown cell model—not evidence that a human clone exists or that personalized replacement organs and therapies are safe, effective, or available.

Why confidence is low

This page marks confidence low because the timeline is speculative. The source set supports that Johnson publicly holds and promotes the goal, but not that immortality by 2039 is scientifically likely. Key missing evidence:

  • independent geroscience forecasts;
  • clinical feasibility of organ-clone drug screening as a generalized anti-aging accelerator;
  • safety/efficacy data for therapies that reverse whole-body biological age without unacceptable cancer or other risks;
  • definitions distinguishing actuarial immortality, longevity escape velocity, negligible senescence, and “not thinking about lifespans.”